SERPLULIMAB: 137 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
137
Total FAERS Reports
36 (26.3%)
Deaths Reported
81
Hospitalizations
137
As Primary/Secondary Suspect
33
Life-Threatening
2
Disabilities
First Report: 20191008 · Latest Report: 20250719
What Are the Most Common SERPLULIMAB Side Effects?
#1 Most Reported
Neutrophil count decreased
19 reports (13.9%)
#2 Most Reported
Platelet count decreased
18 reports (13.1%)
#3 Most Reported
White blood cell count decreased
17 reports (12.4%)
All SERPLULIMAB Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Neutrophil count decreased | 19 | 13.9% | 2 | 13 |
| Platelet count decreased | 18 | 13.1% | 2 | 11 |
| Pneumonia | 17 | 12.4% | 7 | 10 |
| White blood cell count decreased | 17 | 12.4% | 1 | 13 |
| Anaemia | 15 | 11.0% | 0 | 6 |
| Myelosuppression | 13 | 9.5% | 5 | 3 |
| Neutropenia | 11 | 8.0% | 0 | 2 |
| Nausea | 10 | 7.3% | 0 | 1 |
| Thrombocytopenia | 10 | 7.3% | 2 | 2 |
| Off label use | 8 | 5.8% | 6 | 0 |
| Pneumonitis | 8 | 5.8% | 0 | 2 |
| Pyrexia | 8 | 5.8% | 3 | 2 |
| Rash | 8 | 5.8% | 0 | 0 |
| Alanine aminotransferase increased | 7 | 5.1% | 0 | 3 |
| Aspartate aminotransferase increased | 7 | 5.1% | 0 | 3 |
| Hypothyroidism | 7 | 5.1% | 0 | 1 |
| Myocarditis | 7 | 5.1% | 0 | 3 |
| Vomiting | 7 | 5.1% | 0 | 0 |
| Constipation | 6 | 4.4% | 0 | 0 |
| Diarrhoea | 6 | 4.4% | 0 | 0 |
Who Reports SERPLULIMAB Side Effects? Age & Gender Data
Gender: 11.1% female, 88.9% male. Average age: 63.0 years. Most reports from: CN. View detailed demographics →
Is SERPLULIMAB Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2019 | 15 | 2 | 13 |
| 2020 | 40 | 11 | 30 |
| 2021 | 15 | 4 | 11 |
| 2022 | 10 | 1 | 9 |
| 2023 | 10 | 2 | 6 |
| 2024 | 9 | 1 | 7 |
| 2025 | 7 | 0 | 5 |
What Is SERPLULIMAB Used For?
| Indication | Reports |
|---|---|
| Non-small cell lung cancer | 32 |
| Small cell lung cancer extensive stage | 16 |
| Squamous cell carcinoma of lung | 16 |
| Lung neoplasm malignant | 13 |
| Small cell lung cancer | 6 |
SERPLULIMAB vs Alternatives: Which Is Safer?
SERPLULIMAB vs SERTRALINE
SERPLULIMAB vs SEVELAMER
SERPLULIMAB vs SEVOFLURANE
SERPLULIMAB vs SILDENAFIL
SERPLULIMAB vs SILTUXIMAB
SERPLULIMAB vs SIMVASTATIN
SERPLULIMAB vs SINTILIMAB
SERPLULIMAB vs SIPONIMOD
SERPLULIMAB vs SIPULEUCEL-T
SERPLULIMAB vs SIROLIMUS
Official FDA Label for SERPLULIMAB
Official prescribing information from the FDA-approved drug label.